title: [Value of clindamycin in the treatment of ocular toxoplasmosis].
abstract: OBJECTIVE
  Chorioretinal toxoplasmosis can threaten visual function when located in the posterior pole. The aim of this study was to compare the advantages and disadvantage of combination of malocid-sulfadiazine and clindamycin subconjunctivally.
  
  
  METHODS
  Two groups of patients affected by unilateral chorioretinal toxoplasmosis were studied. The diagnosis was performed in 77% of cases on acqueous humor analysis. The first group of twenty-six patients was treated with a combination of malocid-sulfadiazine while the second group (seventeen patients) was treated with clindamycin subconjunctivally. Local and general corticosteroids were associated in all cases. Mean follow-up was 19 months in the first group and 16.5 months in the second.
  
  
  RESULTS
  Visual acuity was increased in 88.5% of cases in the first group and in 94% of cases in the second group. Cicatrization obtained in both groups was comparably delayed 1.68 months for the first and 1.26 months for the second. Recurrences were rarely observed in the two groups: respectively 8% and 6% of cases. No local and general complication was noted.
  
  
  CONCLUSIONS
  These findings suggest the advantages of subconjunctival clindamycin treatment due to the absence of general hematological toxicity.
authors.affiliation: Service du Pr Ayed, Institut Hédi Rais d'Ophtalmologie, Tunis, Tunisie.
authors.forename: A
authors.initials: A
authors.lastname: Jeddi
authors.forename: A
authors.initials: A
authors.lastname: Azaiez
authors.forename: H
authors.initials: H
authors.lastname: Bouguila
authors.forename: M
authors.initials: M
authors.lastname: Kaoueche
authors.forename: S
authors.initials: S
authors.lastname: Malouche
authors.forename: F
authors.initials: F
authors.lastname: Daghfous
authors.forename: S
authors.initials: S
authors.lastname: Ayed
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002648:Child; D002825:Chorioretinitis / Q000188:drug therapy / Q000209:etiology; D002981:Clindamycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011739:Pyrimethamine / Q000627:therapeutic use; D012008:Recurrence; D013411:Sulfadiazine / Q000627:therapeutic use; D014126:Toxoplasmosis, Ocular / Q000150:complications / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D013411:Sulfadiazine; D002981:Clindamycin; D011739:Pyrimethamine